Dry eye market predicts rise to $14.8bn by 2028

The dry eye syndrome (DES) market has been predicted to jump from $4bn in 2018 to $14.8bn in 2028 at a compound annual growth rate of 13.8% across the seven major markets, according to GlobalData research.

Pharmaceutical companies have taken advantage of market gaps by developing innovative DES treatments, including those which address the inflammatory components of DES, as well as stimulation of ocular surface wound healing and the cornea repair process.

Novaliq’s CyclASol product and Novaliq/Bausch + Lomb’s NOV-3 (perfluorohexyloctane) product are examples of novel treatments at the pre-registration stage with the US Food and Drug Administration, which have shown signs of significantly reduced corneal and conjunctival staining and improved ocular dryness.